Seattle, WA -- Scientists at the Pacific Northwest Research Institute (PNRI) in Seattle announced a new biomarker for ovarian cancer today. Their discovery promises improved diagnosis of the disease, which usually remains hidden until it is too late for effective treatment.
In the July 1 issue of Cancer Research, the researchers describe a molecule, HE4, associated with ovarian cancer cells. Because the molecule is secreted readily into the blood, its presence should be detectable when simple and inexpensive clinical blood tests are developed.
"Many cancers have a high cure rate if diagnosed early," Dr. Ingegerd Hellstrom, a principal scientist at PNRI and the lead author of the new paper, says. "But not if diagnosed late. Unfortunately, ovarian carcinoma is most often diagnosed when it is already in an advanced stage. Even after surgery and chemotherapy, relapses are common."
According to the American Cancer Society, the survival statistics are dismal. Three out of four cases of ovarian cancer are diagnosed in late stages. Last year alone, nearly 14,000 women died of the disease.
The best currently available diagnostic test for ovarian cancer is CA125. It is useful in diagnosing late stage cancers, and in detecting the recurrence of tumors after chemotherapy and radiation. But it is not very effective in identifying early stage disease. It also sometimes indicates the presence of ovarian cancer where there is none. Such "false positive" results lead to dangerous, expensive, and unnecessary treatment.
In the Cancer Research study, the new biomarker, HE4, proved to be at least as effective as CA125. And where no false positive results occurred, HE4's sensitivity to ovarian carcinoma was 40% higher than that of CA125.
"I'm very anxious to do something for patients," Hellstrom says. But there is much work to be done, laboratory studies with larger numbers of serum samples, and commercial development to design effective clinical applications of the research. The possibility that a simple and inexpensive blood test can be developed for clinical use is already being studied in a licensing agreement with Fujirebio Diagnostics Incorporated, the creator of CA125.
"Still, this is a step in the right direction," Hellstrom says. "And we are working as passionately and creatively as we can, to curtail this terrible disease."
The above post is reprinted from materials provided by Pacific Northwest Research Institute. Note: Content may be edited for style and length.
Cite This Page: